The Production, Quality Control, and Characterization of ZED8, a CD8-Specific 89 Zr-Labeled Immuno-PET Clinical Imaging Agent.

Autor: Gill H; Genentech Research and Early Development, South San Francisco, California, USA. hermang@gene.com., Seipert R; Genentech Pharmaceutical Technical Development, South San Francisco, California, USA., Carroll VM; inviCRO, Boston, Massachusetts, USA., Gouasmat A; inviCRO, Boston, Massachusetts, USA., Yin J; Genentech Pharmaceutical Technical Development, South San Francisco, California, USA., Ogasawara A; Genentech Research and Early Development, South San Francisco, California, USA., de Jong I; Genentech Pharmaceutical Technical Development, South San Francisco, California, USA., Phan MM; Genentech Research and Early Development, South San Francisco, California, USA., Wang X; Genentech Research and Early Development, South San Francisco, California, USA., Yang J; Genentech Research and Early Development, South San Francisco, California, USA., Ilovich O; inviCRO, Boston, Massachusetts, USA., Marik J; Genentech Research and Early Development, South San Francisco, California, USA., Williams SP; Genentech Research and Early Development, South San Francisco, California, USA.
Jazyk: angličtina
Zdroj: The AAPS journal [AAPS J] 2020 Jan 03; Vol. 22 (2), pp. 22. Date of Electronic Publication: 2020 Jan 03.
DOI: 10.1208/s12248-019-0392-0
Abstrakt: Immuno-PET is a molecular imaging technique utilizing positron emission tomography (PET) to measure the biodistribution of an antibody species labeled with a radioactive isotope. When applied as a clinical imaging technique, an immuno-PET imaging agent must be manufactured with quality standards appropriate for regulatory approval. This paper describes methods relevant to the chemistry, manufacturing, and controls component of an immuno-PET regulatory filing, such as an investigational new drug application. Namely, the production, quality control, and characterization of the immuno-PET clinical imaging agent, ZED8, an 89 Zr-labeled CD8-specific monovalent antibody as well as its desferrioxamine-conjugated precursor, CED8, is described and evaluated. PET imaging data in a human CD8-expressing tumor murine model is presented as a proof of concept that the imaging agent exhibits target specificity and comparable biodistribution across a range of desferrioxamine conjugate loads.
Databáze: MEDLINE